Corcept Q2 FY26 net income rises to $43 million; revenue climbs 32% to $256.1 million - CORT News | RalliesCorcept Q2 FY26 net income rises to $43 million; revenue climbs 32% to $256.1 million
C
CORT• Quarterly results
- Corcept Q2 revenue rose 32% to USD 256.1 million, with Korlym and authorized generic at USD 208.6 million and Lifyorli at USD 47.6 million.
- Net income increased to USD 43 million; diluted EPS climbed to USD 0.36.
- Operating expenses grew to USD 214.8 million, due to spending to launch Lifyorli and investments in the Cushing’s syndrome business.
- Over 1,300 patients have started Lifyorli since the March FDA approval, with demand accelerating each month.
2026 guidance and cash position
- 2026 revenue guidance increased to USD 1.1 billion-USD 1.2 billion; cash and investments totaled USD 544.6 million at June 30.
